Comparison of T-cell receptor diversity of people with myalgic encephalomyelitis versus controls.
Dibble, Joshua J, Ferneyhough, Ben, Roddis, Matthew et al. · BMC research notes · 2024 · DOI
Quick Summary
Researchers studied immune cells called T-cells in people with ME/CFS to see if they were different from those in healthy people. They looked at genetic patterns in blood samples from 40 people in each group: those severely affected by ME/CFS, those mildly or moderately affected, people with multiple sclerosis, and healthy controls. Although they used advanced technology and computer programs to analyze the data, they found that the T-cell patterns were not notably different between the groups.
Why It Matters
Finding objective biomarkers for ME/CFS is critical since no current diagnostic test exists and the disease is often misunderstood or misdiagnosed. This study investigated whether T-cell changes could serve as a biological marker, which could help with diagnosis and understanding disease mechanisms. Although the results were negative, they provide important information about which immune hypotheses may need refinement.
Observed Findings
T-cell receptor sequencing was successfully performed on blood samples from 160 individuals across four groups.
Machine learning analysis failed to achieve statistically significant classification of samples by disease group or severity.
The analytical approach worked well on simulated/artificial datasets but did not translate to distinguishing real patient samples.
No notable TCR diversity differences were consistently identified between ME/CFS patients and controls.
Inferred Conclusions
Altered T-cell receptor diversity in peripheral blood is not a frequent or detectable feature distinguishing people with ME/CFS from controls.
The post-infectious nature of ME/CFS onset may not primarily involve persistent abnormal T-cell activation patterns measurable by TCR repertoire analysis.
Other immune mechanisms or tissue-specific T-cell changes may be more relevant to ME/CFS pathophysiology than circulating TCR diversity.
Remaining Questions
Are T-cell abnormalities present in other tissues (lymph nodes, gut, cerebrospinal fluid) rather than peripheral blood?
Could T-cell dysfunction be related to function or activation state rather than receptor diversity?
What other immune mechanisms—innate immunity, B-cells, cytokines, or autoantibodies—might better explain ME/CFS pathogenesis?
What This Study Does Not Prove
This study does not prove that T-cells are not involved in ME/CFS—only that significant diversity differences in blood T-cell receptors are not a consistent feature detectable by this method. The findings do not rule out T-cell abnormalities in other tissues, different types of immune dysfunction, or abnormal T-cell function rather than diversity. Negative findings in one analysis do not exclude other autoimmune or post-infectious mechanisms.